Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

Protalix BioTherapeutics (PLX) Other Gross PP&E Adjustments (2016 - 2025)

Protalix BioTherapeutics has reported Other Gross PP&E Adjustments over the past 15 years, most recently at $34.2 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $34.2 million for Q4 2025, down 1.93% from a year ago — trailing twelve months through Dec 2025 was $34.2 million (down 1.93% YoY), and the annual figure for FY2025 was $34.2 million, down 1.93%.
  • Other Gross PP&E Adjustments for Q4 2025 was $34.2 million at Protalix BioTherapeutics, up from -$7.8 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for PLX hit a ceiling of $34.9 million in Q4 2024 and a floor of -$7.8 million in Q3 2025.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$5.2 million (2023), compared with a mean of $4.3 million.
  • Peak annual rise in Other Gross PP&E Adjustments hit 12.79% in 2025, while the deepest fall reached 38.35% in 2025.
  • Protalix BioTherapeutics' Other Gross PP&E Adjustments stood at $32.8 million in 2021, then grew by 1.22% to $33.2 million in 2022, then rose by 1.81% to $33.8 million in 2023, then increased by 3.4% to $34.9 million in 2024, then decreased by 1.93% to $34.2 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $34.2 million (Q4 2025), -$7.8 million (Q3 2025), and -$5.0 million (Q2 2025) per Business Quant data.